The global pruritus therapeutics market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of pruritus condition such as urticarial, psoriasis, and atopic dermatitis, and introduction of new products launched by key pharmaceutical companies.
Pruritus refers to itch disorder that can be caused by several ailments ranging from dermatological disorders such as atopic dermatitis, mycoses, contact dermatitis, and chickenpox. Moreover, the dermatologic and systemic causes of pruritus are interlinked. A key dermatologic syndrome is usually diagnosed by a typical itching.
Cholestatic pruritus, renal pruritus, hematologic pruritus, malignancy-associated pruritus, endocrine pruritus, and idiopathic generalized pruritus are all skin diseases associated with pruritus condition. People with chronic renal failure may experience renal pruritus. Furthermore, pruritic patients' skin contains higher quantities of ions such calcium, phosphate, and magnesium. Scratching produces secondary skin disorders such as dryness, infection, excoriation, and contact allergy when severe pruritus is present.
However, chronic pruritus affects people's capacity to function as well as causing mood swings, disrupted sleep patterns, high levels of anxiety leading to despair, and a lower overall quality of life. As a result, industry participants are developing new medications and treatments to help people with persistent skin problems.
Due to the COVID-19 pandemic outbreak, the pruritus market is substantially impacted. However, all major precautions are taken to treat pruritus condition, followed by prescribed guidelines. Alternatively, patients are encouraged telemedicine consultation for follow-ups, and hospitals & clinics are minimizing the contact between patients & staff for the treatment.
Market Trends, Drivers, Restraints, and Opportunities
- Rising cases of dermatological disease influencing the occurrence of pruritus and increasing demand for efficient diagnostics are fueling the market growth in the coming years.
- Increasing development strategies for new drugs for the treatment and robust pipeline products are expected to propel the market growth.
- Lack of understanding of disease pathophysiology and side effects of drugs are some of the major restraining factors hindering the market growth.
- Unavailability of advanced alternatives with better efficacy to treat pruritus is another key factor hampering the market growth.
- Growing research funding by emerging players and favorable regulatory policies for external drugs are expected to offer great opportunity for market expansion in the near future.
Scope of the Report
The report on the global pruritus therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Pruritus Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Types (Allergic Contact Dermatitis, Urticaria, Atopic Dermatitis, and Others) and Products (Local Anesthetics, Corticosteroids, Antihistamines, Counterirritants, Calcineurin Inhibitors, Immunosuppressant, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Uloric; Cara Therapeutics; UCB Pharma; Sanofi Aventisand; Actavis Plc; and Pfizer, Inc.
|
Market Segment Insights
Allergic contact segment is expected to grow at a robust pace
Based on types, the global pruritus therapeutics market is segmented into allergic contact dermatitis, urticaria, atopic dermatitis, and others. The allergic contact segment is expected to grow at a robust pace during the forecast period. It is the third most prevalent reason for patients to take advice from dermatologist. Furthermore, the growing popularity of ear, navel, and nose piercing, allergic contact dermatitis is becoming more common in women.
As per reports, nickel allergies affect around 20% to 40% of women. In the US, the prevalence of contact dermatitis ranges from 1.5% to 5.4% and it accounts for 95% of all reported occupational skin diseases. Thus, it is expected to boost the segment growth in the coming years.
Corticosteroids segment is projected to expand at a considerable CAGR
On the basis of products, the market is segregated as local anesthetics, corticosteroids, antihistamines, counterirritants, calcineurin inhibitors, immunosuppressant, and others. The corticosteroids segment is projected to expand at a considerable CAGR during the forecast period. The growth of the segment is attributed to the wide usage of the products to provide relief from atopic dermatitis or psoriasis and increasing demand for over the counter topical corticosteroids. Furthermore, corticosteroids are mostly used as the first line of treatment products associated with pruritus condition.
Moreover, corticosteroids are used to treat skin disorders as they reduce the amount of collagen produced in the skin that further diminishes inflammation. It comes in topical forms such as lotions, ointments, shampoos, creams, mousses, gels and tapes that can be applied to the skin. Furthermore, rashes can be effectively treated with a range of corticosteroids and other anti-inflammatory lotions that can be applied to the skin. Thus, it is estimated to upsurge the segment growth.
North America is anticipated to constitute a key market share
In terms of regions, the global pruritus therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the presence of favorable government initiatives, introduction of new products, rising prevalence of target diseases, and the presence of pruritus encouraging climate condition in the region.
Segments
Segments Covered in the Report
The global pruritus therapeutics market has been segmented on the basis of
Types
- Allergic Contact Dermatitis
- Urticaria
- Atopic Dermatitis
- Others
Products
- Local Anesthetics
- Corticosteroids
- Antihistamines
- Counterirritants
- Calcineurin Inhibitors
- Immunosuppressant
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Some of the key players competing in the global pruritus therapeutics market are Uloric; Cara Therapeutics; UCB Pharma; Sanofi Aventisand; Actavis Plc; and Pfizer, Inc. These companies are implementing strategies such as technological advancements, innovative solution, new developed product launches, research initiatives, merger & acquisitions, and regional expansions to secure their advantageous position in the pruritus therapeutics market.
For instance, in August 2020, MC2 Therapeutics, a Europe-based company entered into a partnership with EPI Health, LLC to market its Wynzora Cream in the US. Furthermore, MC2 Therapeutics has received Wynzora’s United States Food and Drug Administration (USFDA) approval for the treatment of plaque psoriasis in adults in July 2020.
Cara Therapeutics, a clinical-stage biopharmaceutical company, has announced the successful completion of its Phase-II dose-ranging trial of oral Korsuva for moderate to severe chronic kidney disease associated with pruritus in June 2020. On the other hand, Menlo Therapeutics Inc. has publicized the top-line results from two recent Phase-III clinical trials investigating the accuracy and safety of oral serlopitant for the cure of pruritus associated with prurigo nodularis in April 2020.
Request For Customization
Enquiry Before Buying
Speak With Analyst
